12:00 AM
 | 
Oct 13, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CX3C motif receptor 1 (CX3CR1)

Inflammation

INDICATION: Shock / trauma

Mouse studies suggest inhibiting CX3CR1 could help treat the chronic phase of traumatic brain injury (TBI). In a mouse model of chronic-phase TBI, CX3CR1 knockout decreased...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >